Scilex Holding announced that it has signed an insurance coverage agreement for ELYXYB with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB. “We are pleased to report solid ELYXYB growth in managed plans for additional points of care and expanded utilization of ELYXYB throughout the U.S. Importantly, our diversified portfolio of unique products will increasingly allow us to offer patients complementary and standalone opioid-sparing pain management solutions. The Scilex commercial team continues to demonstrate success in expanding access and currently has prioritized and targeted select payor accounts to improve the access for ELYXYB(R),” said Jaisim Shah, Chief Executive Officer and President of Scilex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCLX:
- Scilex’s ZTlido will be added as preferred agent to Medicaid PDL in two states
- Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State
- Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee
- Scilex announces addition of ZTlido as preferred agent to Medicaid PDL
- Scilex reports November ZTildo gross sales $14M-$15M